AXA1125
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
AXA1125 or LIVRQNac is a new drug developed by Axcella Therapeutics which is currently in clinical trials for post-exertional fatigue caused by Long COVID.[1][2] AXA1125 has been described as a "novel composition of amino acids" and a "metabolic modulator" and consists of five amino acids (arginine, glutamine, isoleucine, leucine, and valine) and N-acetylcysteine (NAC).[3]
Theory
AXA1125 is a endogenous metabolic modulator, which means it consists of naturally occurring substances that act in a way that modulates energy metabolism.[3] AXA1125 was designed to treat non-alcoholic liver conditions.[3]
Amino acids and precusors
AXA1125 consists of a combination of:
- Arginine
- Glutamine
- Isoleucine
- Leucine
- Valine
- N-acetylcysteine (NAC), a precursor to several amino acids[3]
Evidence
Clinicians
Risks and safety
Costs and availability
Axcella Therapeutics, the company producing and studying the drug, has closed. [4]
See also
Learn more
- Oxford test potential treatment for fatigue in long COVID patients - Oxford University
- Poster: Mechanistic Insights Into AXA1125, a Novel Endogenous Metabolic Modulator Composition, Targeting Multiple NASH Drivers - Axcella Health Inc.
References
- ↑ "Oxford to test potential treatment for fatigue in long COVID patients". University of Oxford. Retrieved October 31, 2021.
- ↑ "Axcella commences trial of AXA1125 for Long COVID treatment". clinicaltrialsarena.com. Retrieved October 31, 2021.
- ↑ 3.0 3.1 3.2 3.3 Hamill, Michael J.; Nadine Daou; Arianna Nitzel; Lorena Pantano; Margaret Koziel; Manu V. Chakravarthy (March 2021). "Mechanistic Insights Into AXA1125, a Novel Endogenous Metabolic Modulator Composition, Targeting Multiple NASH Drivers" (PDF). Axcella Health Inc.
- ↑ "Axcella Health Becomes the Latest Flagship Company to Close its Doors". BioSpace. Retrieved May 8, 2024.
